← FDA Drug Approvals (Drugs@FDA)
EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: APOTEX · Approved 2026-01-30
Drug application
- FDA Application #
ANDA214095- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE
- Generic name
- Emtricitabine
- Active ingredients
- EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
- Sponsor
- APOTEX
- First approval
- 2026-01-30
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown